Prof Jorge Correale and Dr Lilyana Amezcua talk to The Lancet Neurology about their Personal View papers, published in the October 2024 issue, on the differential diagnosis of multiple sclerosis in regions outside North America and Western Europe and in people from minority ethnic or racial backgrounds in North America, northern Europe, and Australasia.

Dr Alex Iranzo joins The Lancet Neurology to discuss his recent Review on the association between sleep disorders and Parkinson's disease. The Review is published in the August issue of The Lancet Neurology.

Dr Glenn Nielsen joins Lauren Southwell to discuss the Physio4FMD trial of specialist physiotherapy for people with functional motor disorder in England and Scotland. This Article is published in the July issue of The Lancet Neurology.

Sanjay Sisodiya joins The Lancet Neurology to discuss the potential effects of climate change on brain health. The Personal View is published in the June issue of The Lancet Neurology.

Jacqueline French and Jacob Pellinen join Senior Editor Sarah Passey to discuss recent progress made in the diagnosis of epilepsy and challenges that remain. Their Review on this topic is published in the May issue of The Lancet Neurology.

Jaimie Steinmetz and Theo Vos from the Institute of Health Metrics and Katrin Seeher and Tarun Dua from WHO join Heather Brown and Lauren Southwell to discuss new data on the global, regional, and national burden of disorders affecting the nervous system. The Article is published in the April issue of The Lancet Neurology.

Giovanni Frisoni joins The Lancet Neurology to discuss new European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. The Personal View is published in the March issue of The Lancet Neurology.

Marianne Chapleau and Gil Rabinovici join Senior Editor Sarah Passey to discuss their research on posterior cortical atrophy. The Article is published in the February issue of The Lancet Neurology.

Cecilia Åkerlund and David Nelson join The Lancet Neurology to discuss their research on clinical variables that might distinguish how the disease process progresses in people with traumatic brain injury. The Article is published in the January issue of The Lancet Neurology.

Rustam Al-Shahi Salman joins Senior Editor Sarah Passey to discuss the COCROACH meta-analysis findings, published in the December issue of The Lancet Neurology, of the effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage.

Njideka Okubadejo and Mie Rizig join The Lancet Neurology to discuss their comprehensive genome-wide assessment in African and African admixed individuals with the aim of developing a better understanding of the genetic architecture of Parkinson's disease in these underserved populations.

Anthony Feinstein (University of Toronto and Sunnybrook Health Sciences Centre, Toronto, Canada) discusses CogEx, a randomised trial of cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis. The Article is published in the October issue of The Lancet Neurology.

William Jagust (University of California in Berkeley, CA, USA) talks to Senior Editor Sarah Passey about the complex pathway between amyloid β and cognition, and implications for therapy for people with Alzheimer’s disease. His Personal View on this topic is published in the September issue of The Lancet Neurology.

Stephen Strittmatter (Yale School of Medicine, CT, USA) discusses his first-in-human and randomised trial of a soluble Nogo-receptor-Fc decoy in patients with chronic cervical spinal cord injury. The Article is published in the August issue of The Lancet Neurology.

Benzi Kluger (University of Rochester Medical Center, Rochester, NY, USA), Claire Creutzfeldt (University of Washington, Seattle, WA, USA), and Malenna Sumrall (University of Colorado Anschutz Medical Campus, Aurora, CO, USA) join Jonathan Blott to discuss palliative care for individuals with neurological diseases, exploring the challenges and opportunities in enhancing the quality of life for those affected by neurological conditions. Their Review is published in the July issue of The Lancet Neurology.

Andrew Cole (Massachusetts General Hospital Epilepsy Service, Boston, MA, USA) talks to Senior Editor Sarah Passey about the complexities underlying epilepsy in people with glioblastoma. His Review on this topic is published in the June issue of The Lancet Neurology.

Karen Duff and Connor Langworth-Green (University College London, London, UK) discuss tauopathies and the chronic effects of inflammation on this group of disorders. Their Personal View on this topic is published in the May issue of The Lancet Neurology.

Kerstin Hellwig (Ruhr University Bochum, Bochum, Germany) discusses family planning considerations in multiple sclerosis. This Review is published in the April issue of The Lancet Neurology.

Geraldine Dawson (Duke University School of Medicine, NC, USA) discusses the latest advances and ongoing challenges in prediction of autism during infancy. This Review is published in the March issue of The Lancet Neurology.

Ellisiv Mathiesen (The University of Tromsø – the Arctic University of Norway, Tromsø, Norway) discusses the findings of the TWIST trial, which investigated the use of tenecteplase for patients with wake-up stroke who were selected for treatment by non-contrast CT. This Fast-track Article is published in the February issue of The Lancet Neurology.

Mark Hallett (National Institute of Neurological Disorders and Stroke, Bethesda, MD, USA) discusses his Review, published in the June issue of The Lancet Neurology, on functional neurological disorder, and talks about new subtypes of this disorder, diagnostic challenges, and how education is important.

Bruce Campbell joins The Lancet Neurology to discuss his systematic review of the HERMES collaboration.

Beau Ances (Washington University in St Louis, MO, USA) discusses recent research on amyloid biomarkers in people with genetic forms of Alzheimer’s disease; his Article is published in the January issue of The Lancet Neurology.

Axel Petzold (National Hospital for Neurology and Neurosurgery and Moorfields Eye Hospital, London, UK, and Amsterdam University Medical Center, Amsterdam, Netherlands) discusses a Position Paper, published in the December issue of The Lancet Neurology, which sets out new criteria for the diagnosis and classification of optic neuritis.

Maeike Zijlmans (University Medical Center Utrecht, Utrecht, Netherlands) discusses recent research on tailoring of epilepsy surgery with biomarkers on intraoperative electrocorticography, and describes some of the challenges of this technique and what the future steps are for the field.

Jerome Siegel (University of California, Los Angeles, CA, USA) discusses sleep research in hunter-gatherer populations and what we can learn from the sleep habits of various species; his Review is published in the October issue of The Lancet Neurology, which is the fourth paper in The Lancet’s Series on sleep and sleep disorders.

Laurent Servais and Dora Markati (both from the University of Oxford, UK) discuss emerging therapies for Duchenne muscular dystrophy; their Review is published in the September issue of The Lancet Neurology.

Andreas Charidimou (Massachusetts General Hospital, Boston, MA, USA) discusses an international collaborative study that presents new Boston criteria for diagnosis of cerebral amyloid angiopathy; the Article is published in the August issue of The Lancet Neurology.

Sarah Tabrizi (UCL Queen Square Institute of Neurology, London, UK) and Cristina Sampaio (CHDI Foundation, Princeton, NJ, USA) discuss two papers on Huntington’s disease published in the July issue of The Lancet Neurology: a Position Paper outlining a new classification of the disease, called the Huntington’s Disease Integrated Staging System, and a Personal View on potential disease-modifying therapies.

Eva Feldman (University of Michigan, Ann Arbor, USA) discusses the latest advances in the genetics, risk factors, pathophysiology, therapeutic development, and the diagnosis and prognosis of amyotrophic lateral sclerosis; the Series is published in the May issue of The Lancet Neurology.

Estrella Morenas-Rodriguez and Christian Haass (German Centre for Neurodegenerative Diseases, Munich, Germany) discuss their recent research, published in the April issue of The Lancet Neurology, on soluble TREM2 and its association with Alzheimer’s disease biomarkers and cognition.

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Giuseppe Citerio (University of Milano-Bicocca, Milan, Italy) discusses the implications of a study from the CENTER-TBI project of the effect of frailty on 6-month outcome after traumatic brain injury, which is published in the February issue of The Lancet Neurology.

Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology.

Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.

Antonio Uccelli (University of Genoa) discusses his research, published in the November issue of The Lancet Neurology, on the therapeutic use of mesenchymal stem cells for multiple sclerosis.

Priya Palta (Columbia University, New York) explains the importance of blood pressure control in the prevention of cognitive decline. Her Review, published in the October issue of The Lancet Neurology, provides an update of the mounting evidence that links hypertension with dementia risk.

Adam Boxer (University of California, San Francisco) discusses his research, published in the September issue of The Lancet Neurology, on diagnostic performance of tau biomarkers in neurodegenerative diseases.

Irene Cortese (National Institute of Neurological Disorders and Stroke) discusses the difficulties of designing clinical trials in progressive multifocal leukoencephalopathy.

Doug Turnbull (University of Newcastle) discusses mitochondrial diseases in adults, which are reviewed in the July issue of The Lancet Neurology, and explains how important these diseases are for neurologists.

Geert Jan Biessels (University Medical Centre Utrecht) discusses his research, published in The Lancet Neurology June issue, on using strategic infarct locations to predict post-stroke cognitive impairment.

Henk-Jan Westeneng discusses his new work on the causal effects of pre-symptomatic lifestyle on ALS.

Anne MacGregor discusses her recent Review of menstrual migraine, and explains why this disease needs greater recognition.

Peter Rothwell (Oxford University) discusses his new research, found in our new issue, on asymptomatic carotid stenosis and stroke.

Professor Michael Fehlings discusses the implications of his two papers in the Feb 2021 issue of The Lancet Neurology.

Emma Jones and Simon Mead discuss their article in The Lancet Neurology, identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease.

Mark Obermann discusses his study examining the use of prednisone for the short-term prevention of cluster headache.

Robert Innis discusses his work on measuring neuroinflammation using PET imaging.

Tom Solomon discusses his Rapid Review on neurologically-associated COVID-19 problems, in The Lancet Neurology.

Huda Zoghbi discusses the prospects for future therapies in Rett syndrome.

Bas Bloem chats about his new research into a network model for reshaping chronic neurological care for patients with Parkinson's disease.

Sarah Tabrizi discusses her new research into analysing the early onset of Huntington's Disease.

Meng-Chuan Lai discusses the current evidence base for supporting autistic people.

Tobias Derfuss discusses his rapid review on advances in oral immunomodulating therapies in relapsing multiple sclerosis.

Andrea Winkler discusses the global burden caused by stroke, epilepsy, dementia, and neuroinfections, and what low- and middle-income countries can do.

Jonathan Schott discusses the associations between blood pressure across adulthood and late-life brain structure and pathology.

Jeffrey Wozniak talks about his Review in The Lancet Neurology, on clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder.

Martin Dichgans discusses advancements in the field of stroke genetics.

Brent Fogel talks to The Lancet Neurology about his work on large-scale genomic analysis.

Amaia Arranz and Bart De Strooper discuss their Review on the role of astroglia in Alzheimer's disease.

Michael Irwin (University of California, Los Angeles, USA) discusses a Review concerning potential links of sleep disturbance and possible increased risk of Alzheimer's disease dementia.

Lindsay Wallace and Kenneth Rockwood join The Lancet Neurology to talk about their work on the association between frailty and the onset of Alzheimer's disease.

In the latest podcast from The Lancet Neurology, Jan Scheitz discusses the development of stroke–heart syndrome.

Mark Cook and Phillippa Karoly join The Lancet Neurology to discuss their retrospective study of cyclical patterns in epileptic seizures.

Bruce Trapp and Daniel Ontaneda discuss their retrospective study investigating cortical neuronal loss and cerebral white-matter demyelination in mulitple sclerosis.

Josep Dalmau joins The Lancet Neurology to discuss recognition and outcomes of autoimmune encephalitis after herpes simplex encephalitis.

David Eidelberg and Katharina Schindelbeck join The Lancet Neurology to explain their new review of the applications of network imaging biomarkers in Parkinson's disease.

Eugene Major and David Clifford join The Lancet Neurology to discuss their review of pathogenesis and treatments for progressive multifocal leukoencephalopathy.

Torbjörn Tomson discusses the issue of antiepileptic drugs during pregnancy and the risk of major congenital malformations.

Christian Elger discusses the diagnostic challenges in epilepsy with the detection and reporting of seizures.

Jeffrey Cohen joins us to talk about the process of updating and revising the McDonald criteria for diagnosis of MS.

Jose Bras discusses his study of the genetic architecture of dementia with Lewy bodies.

Andrew Maas and David Menon, lead authors, discuss The Lancet Neurology Commission on traumatic brain injury and outline the worldwide burden.

Keith Josephs talks about considering TDP-43 as a potential factor related to increased rates of hippocampal atrophy in patients with Alzheimer's disease.

Cathy Stinear discusses her review of biomarkers that might predict motor recovery after stroke.

Lesley Jones and Sarah Tabrizi talk about their work on the identification of genetic markers associated with the progression of Huntington's disease.

Jeremy Chataway discusses the surprising effects of simvastatin on patients with secondary progressive multiple sclerosis.

Adam Boxer offers an overview of the latest on diagnosis and treatment for progressive supranuclear palsy.

Eva Feldman discusses the neurological consequences of obesity.

Marc Diamond discusses his Personal View on the prion model for progression and diversity of neurodegenerative diseases.

Randall Bateman and Nick Fox discuss what they've learned from their papers on Alzheimer's disease.

Professor Thomas Similowski discusses his surprising study on the effectiveness of non-invasive ventilation for patients with amyotrophic lateral sclerosis.

Dr. Kiran Maski discusses insomnia, parasomnia, and narcolepsy in children.

Dr. Gustavo Saposnik discusses the efficacy of non-immersive virtual reality exercise in the treatment of stroke.

Professor Valery Feigin discusses an Article on the global burden of stroke and risk factors from 1990–2013.

Annemieke Aartsma-Rus and Elizabeth Vroom discuss with Patricia Lobo the developments in Duchenne muscular dystrophy therapy and how this can serve as a paradigm for development of treatment for rare diseases.

Richard Lane interviews John Hardy, Jonathan Rohrer and Sarah Tabrizi, who are members of the Scientific Committee.

Francesc Graus and Josep Dalmau discuss new criteria for a clinical approach for the diagnosis of autoimmune encephalitis.

Rustam Salman discusses how the assessment of cerebral cavernous malformations can help identify people at risk of subsequent brain haemorrhage.

Bas Bloem talks about ParkinsonNet, a healthcare model that supports a multidisciplinary network for people with Parkinson’s disease.

Clifford Jack from the Mayo Clinic discusses a research article which investigates the role of biomarkers to help identify preclinical dementia.

Chris McDermott and Richard Lane discuss the DiPALS study, investigating the effect of diaphragm pacing in addition to non-invasive ventilation in patients with ALS.

Bruce Campbell discusses the remarkable benefits of endovascular treatment for ischaemic stroke.

Jalesh Panicker discusses lower urinary tract dysfunction, a common problem in people with neurological disorders.

Daniel Lowenstein discusses research into status epilepticus.

Paul Krack discusses apathy in Parkinson's disease.

In an interview Michael Heneka considers the contribution of neuroinflammatory mechanisms to Alzheimer’s disease pathogenesis.

Steven Goodrick talks to Jonathan Rohrer about the latest research in C9orf72 expansions.

Alan Thompson and Steven Goodrick discuss a new three-part Series on progressive MS. 

Gabrielle deVeber discusses a Review on childhood stroke.

Jonathan Smith discusses how assessment of pain in elderly adults with dementia differs from that in healthy elderly adults.

Professor Ammar Al-Chalabi discusses a population based modelling study of the development of amyotrophic lateral sclerosis.

Steven Galetta discusses his Review on how tests of visual function can be useful in the assessment of minor head injury and TBI.

Sir Graham Teasdale reflects on the Glasgow COMA scale for brain injury, 40 years after it was published in The Lancet.

John Hardy discusses a genome-wide association study on frontotemporal dementia and its subtypes.

David Bennett discusses painful and painless channelopathies.

Dr. David McDonagh and Professor Mark Newman discuss the neurological complications of cardiac surgery.

Craig Anderson discusses findings from a study about the effects of blood pressure variability on outcomes for patients with intracerebral haemorrhage.

Henrik Hagberg discusses the role of mitochondria in CNS development and in the injury responses of the developing brain.

Finbar O'Callaghan from the Institute for Child Health, London, discusses new research about the incidence and risk factors for childhood stroke.

In an extended interview, Nicholas Abend from the Children's Hospital of Philadelphia discusses a Review on electrographic seizures and status epilepticus in critically ill children and neonates with encephalopathy.

Hugh Marcus from the University of Cambridge discussing a Review on stroke and TIA in the posterior territory.

Francisco Javier Carod-Artal discusses a Review concerning the neurological complications of dengue virus infection.

Paul Hagerman discusses a Review which highlights the latest clinical and molecular understanding of the FMR1 mutation and FXTAS.

Sarah Tabrizi discusses the latest findings of the TRACK HD study concerning Huntington's disease.

Klaus Fassbender discusses a Review about streamlining pre-hospital management of stroke.

Joanna Wardlaw discusses the poorly understood condition of cerebral small vessel disease.

Jim Barkovich from UCSF discusses a Review about midbrain and hindbrain disorders.

Kim Meador explains the effects of fetal exposure to anti-epileptic drugs, plus other highlights from the March issue.

Josep Dalmau describes the clinical and pathological features of anti-NMDA receptor encephalitis.

Roger Barker discusses fetal dopaminergic transplantation as a therapeutic option for Parkinson's disease.

Eric Reiman discusses a research article, where biomarker changes are assessed in early onset Alzheimer's disease.

Marjo van der Knaap discusses megalencephalic leukoencephalopathy with subcortical cysts.

Bjarne Udd discusses the myotonic dystrophies.

Frank Gilliam discusses the adverse effects of anti-epileptic drugs.

Highlights from the August issue, and Dag Aarsland discusses dementia in patients with Parkinson's disease.

Justin McArthur discusses CNS opportunistic infections within the context of HIV.

Brian Callaghan discusses a Review about diabetic neuropathy.

Hudson Freeze discusses a Review about the neurology of inherited glycosilation disorders.

Peter Langhorne discusses the potential of specialist stroke units in low and middle-income settings.

Kailash P Bhatia discusses a Review on the epidemiology, clinical features, diagnosis, and treatment of functional movement disorders.

Discussion of a Review about posterior cortical atrophy, and other issue highlights.

Discussion of the links between nutrition and stroke risk.

Brenda Banwell discusses the potential of MRI screening after a first demyelinating event as a future predictor of MS in children.

Chris Polman discusses a Rapid Review of new oral therapies for patients with multiple sclerosis.

Ashfaq Shuaib talks about collateral blood flow in the brain as a potential therapeutic target for patients with acute ischaemic.

How Alzheimer's disease prevalence could be associated with modifiable risk factors.

August issue highlights, including discussion of a genetic association study concerning intracerebral haemorrhage.

July issue highlights, including discussion of the EURAP Registry concerning a possible association between anti-epileptic drugs and congenital birth defects.

Bas Bloem discusses a review in the June issue about postural abnormalities associated with Parkinson's disease.

Discussion of new data from the ADAGIO trial for the treatment of Parkinson's disease, and a Canadian cohort study assessing risk factors for multiple sclerosis in children.

Highlights from the April issue with a focus on aneurysmal subarachnoid haemorrhage.

Highlights from the March issue with a focus on neurodegenerative disease.

Prozac and motor function after stroke, and the effect of rapid hypothermia after brain injury.

January highlights, including discussion of research from the TRACK-HD study for Huntington's disease.

Discussion of the RE-LY trial subgroup for the secondary prevention of stroke, and phase 2 results of gene therapy for Parkinson's disease.

October issue highlights, including cilostazol compared with aspirin for secondary stroke prevention.

September issue highlights, including the effects of a longer treatment window with alteplase after stroke, and discussion of a Review about ataxia.

The use of blood-pressure-lowering therapy after stroke, limbic encephalitis, and discussion of Huntington's disease prevalence.

July highlights, including ultrasound to detect asymptomatic carotid stenosis in stroke prevention.

June issue highlights, including discussion of depression and Parkinson's disease.

Lithium therapy and ALS, and stroke associated with Chaga's disease.

Discussion of April issue highlights, including the International Carotid Stenting study.

Discussion of concerns over generic substitution of antiepileptic drugs.

Alison Rowan discusses issue highlights, including PET imaging for the diagnosis of Parkinson's disease.

Kate Bushby discusses two reviews on Duchenne Muscular Dystrophy.

Discussion of the BENEFIT study for MS and the role of elderly people in neurological research.

Discussion of the CAVATAS trial for carotid stenosis.

Helen Frankish discusses articles about Huntington's disease and stroke.

Discussion of deep-brain stimulation for cerebral palsy, and rehabilitation interventions for motor recovery after stroke.

Alison Rowan discusses epilepsy services in the UK, and a review about CADASIL.

Helen Frankish discusses research on childhood stroke, and add-on drug therapy for MS.

Elena Becker-Barroso discusses the ISAT study follow-up, and paracetamol use in acute stroke.

Helen Frankish discusses the global incidence of stroke, and a research article assessing the malaria drug quinacrine for the treatment of prion disease.

Helen Frankish discusses articles on stroke prevention after TIA, and the potential of stem-cell therapy for the treatment of multiple sclerosis.

Helen Frankish discusses antipsychotics and Alzheimer's disease, and desmoteplase for ischaemic stroke.

Helen Frankish discusses articles about galantamine for severe Alzheimer's disease, and a genome-wide association study about CJD.

Helen Frankish discusses articles on NMDA-receptor encephalitis, perilesional brain oedema, and looks ahead to the TLN stroke conference in Beijing.

In this month's Lancet Neurology Podcast, Editor Helen Frankish discusses two research articles: one on the treatment of hemicrania continua, and another on perception of pain in a minimally conscious state. Also discussed is a review on sudden unexpected death in epilepsy.

Helen Frankish discusses highlights from the October issue, including follow-up results for trials comparing carotid stenting with endarterectomy in patients with stenosis; and the PRoFESS study comparing drug combinations to reduce the severity of recurrent ischaemic stroke.

Elena Becker-Barroso discusses highlights from the September issue, including the potential of PB2 to slow the development of amyloid beta in patients with Alzheimer's, and how telemedicine could improve stroke treatment.

Helen Frankish discusses biomarkers for indications of dementia, and other highlights from the August issue.

The International LRRK2 Consortium, which includes investigators in 21 centres, has collected data from almost 20000 patients with Parkinson's disease carrying mutations in the LRRK2 gene. The Lancet Neurology editor Elena Becker-Barroso and Daniel Healy, the corresponding author on their first report, summarises the findings and their implications in clinical practice in a podcast.

Editor Helen Frankish discusses highlights from the June issue: a randomised trial showing the efficacy of a ketogenic diet to protect against childhood epilepsy; and a trial with phase II results for the Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease.

Editor Helen Frankish discusses highlights from the May issue: results from the INTERACT trial showing how intensive blood pressure lowering could be beneficial for people who have had intra cranial haemorrhage; also discussion of a genetic study identifying a gene mutation involved in amyloid lateral sclerosis, and a review of stroke in children.

Editor Helen Frankish discusses highlights from the April issue: including the EPITHET study of alteplase treatment 3-6 hours after a stroke, and donepezil treatment in patients with CADASIL, a genetic form of vascular dementia.

Editor Helen Frankish discusses highlights from the March issue: including research Articles about a genetic clue to the cause of dystonia, a neurological disorder relating to Parkinson's disease; and a study identifying older age (68 years) as a risk factor for stroke among people given stenting rather than Endarterectomy to unblock the carotid artery.

Imaging of amyloid β in Alzheimer's disease with a novel PET tracer Amyloid β (Aβ) deposits can be imaged by PET, but most Aβ PET ligands are not suitable for clinical diagnosis of Alzheimer's disease (AD). To test the effectiveness of a new Aβ PET ligand, 18F-BAY94-9172, Christopher Rowe and colleagues compared its binding with Aβ deposition in patients with AD, individuals with frontotemporal lobar degeneration, and healthy controls. Helen Frankish discusses the study in this month's podcast, and highlights the editorial concerning the possible tagging of individuals with AD.

Epilepsy in children encompasses several syndromes that have different prognoses but are all characterised by a predisposition to recurrent seizures; therefore, treatment has to be tailored to the individual. Any treatment regimen for children with epilepsies should have rational goals, take into account the additional morbidities that are commonly found in these patients.

Editor Helen Frankish discusses highlights from the December issue: original research investigating the efficacy of minocycline for the treatment of amyotrophic lateral sclerosis (ALS); a randomised trial assessing the effect and treatment duration of topiramate for the prevention of migraine; and a brief discussion of a review about medulloblastoma in children.

Editor Helen Frankish discusses highlights from the November issue: two Articles looking at the early treatment of minor strokes or transient ischaemic attacks and the risk of stroke, an Editorial calling for more funding for headache research, and a large multinational study identifying genetic variants that influence the development of epilepsy.

Editor Helen Frankish discusses this month's leading edge editorial: the unsuccessful appeal against the UK National Institute for Health and Clinical Excellence (NICE) after its recent decision to not make dementia therapies widely available in the UK on grounds of cost-effectiveness

Editor Helen Frankish discusses highlights from the September issue: an association between Epstein-Barr virus and acquisition of multiple sclerosis in children; and current opportunities for the development of anti-epileptic drugs. Epilepsy and HIV are also discussed in this month's leading edge editorial.

Editor Helen Frankish discusses two topics from the August issue: a research article suggesting people with epilepsy are three times more likely than the general population to commit suicide; and she interviews the author of a position paper about a new research framework for the diagnosis of Alzheimer's disease.

In this month's Lancet Neurology podcast Helen Frankish discusses a research article concerning numerous factors which determine the risk of recurrent venous thromboembolism after cerebral venous thromboembolism in children. Also discussed is the Leading Edge editorial calling for a more modern approach to stroke services in the UK, and the review about silent infarcts, which could be a useful way of detecting neurological disease before symptoms develop.

Editor Helen Frankish discusses highlights from the June issue: research from the University of Oxford about the incidence of haemorragic stroke; while incidence has decreased in younger age groups over the past two decades, inclusion of data from people aged over 75 years shows how overall incidence has remained the same, underlining the need for the inclusion of older people in stroke research. Also discussed is the comprehensive review on migraine and this month's editorial about stem-cell research in the USA.

Editor Helen Frankish discusses highlights from the May issue. The GIST trial concerning blood glucose levels after stroke, despite being stopped early, has implications for future research in this area.

Editor Helen Frankish discusses the April issue, including promising research on occipital-nerve stimulation for cluster headache, and a new method to aid the diagnosis of Lewy body dementia.

Editor Helen Frankish discusses highlights from the March issue: a pooled analysis of three randomised trials which shows how decompression surgery soon after stroke onset can reduce mortality.

This month's podcast discusses the themed stroke issue coinciding with the International Stroke Conference taking place in San Francisco in early February. Also discussed is the first of a series of articles on stroke in developing countries.

Highlights from the January issue of The Lancet Neurology, includes a research article on epilepsy in sub-Saharan Africa and the Leading Edge urging WHO to prioritise neurological diseases.

December's Listen to The Lancet Neurology highlights the negative outcome of a trial of the drug TCH346 as a neuroprotective agent for Parkinson's disease, a Review about meningiomas, and depression among people with neurological disease.

Editor Helen Frankish discusses the highlights from the November issue, which this month has a focus on Parkinson's disease.

October's TLN podcast includes a discussion of a paper on epilepsy in China, and a Forum article on possible infectious causes of multiple sclerosis.

Dr Adrian Owen joins Sarah Passey to chat about a his Personal View, published in the August 2024 issue of The Lancet Neurology, about detecting awareness after an acute brain injury.